| Literature DB >> 28423054 |
Chan-Won Kim1, Yoosoo Chang1,2,3, Eunju Sung1,4, Kyung Eun Yun1, Hyun-Suk Jung1, Byung-Joon Ko1, Min-Jung Kwon1,5, Young Youl Hyun6, Kyu-Beck Lee6, Hyang Kim6, Hocheol Shin1,4, Seungho Ryu1,2,3.
Abstract
BACKGROUND: It is unclear whether sleep duration and quality are associated with chronic kidney disease (CKD) and glomerular hyperfiltration. The aim of this study was to examine the association of sleep duration and quality with CKD and glomerular hyperfiltration in young and middle-aged adults.Entities:
Mesh:
Year: 2017 PMID: 28423054 PMCID: PMC5396878 DOI: 10.1371/journal.pone.0175298
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Baseline characteristics of study participants by sleep duration among men.
| Characteristics | Overall | Sleep duration (hours) | |||||
|---|---|---|---|---|---|---|---|
| ≤ 5 | 6 | 7 | 8 | ≥ 9 | |||
| 135,633 | 21,081 | 55,249 | 45,242 | 12,533 | 1,528 | ||
| 41.0 (9.0) | 40.7 (8.9) | 40.6 (8.2) | 41.0 (9.0) | 42.5 (10.9) | 46.2 (14.3) | <0.001 | |
| 66.3 | 72.0 | 67.5 | 63.0 | 63.0 | 65.8 | <0.001 | |
| 39.4 | 44.5 | 40.0 | 37.2 | 36.1 | 36.8 | <0.001 | |
| 38.6 | 42.8 | 38.4 | 37.3 | 37.2 | 39.0 | 0.136 | |
| 36.7 | 40.8 | 36.9 | 34.8 | 35.2 | 39.0 | 0.119 | |
| 17.6 | 18.0 | 17.3 | 17.4 | 18.6 | 20.6 | <0.001 | |
| 86.8 | 87.0 | 89.2 | 87.0 | 78.8 | 58.5 | <0.001 | |
| 81.0 | 76.1 | 80.9 | 82.7 | 83.6 | 78.5 | <0.001 | |
| 7.8 | 12.9 | 7.4 | 6.1 | 6.6 | 11.4 | 0.196 | |
| 16.5 | 17.3 | 16.0 | 16.0 | 18.2 | 24.4 | <0.001 | |
| 6.1 | 6.8 | 5.5 | 5.8 | 7.4 | 12.8 | <0.001 | |
| 1.6 | 1.7 | 1.4 | 1.5 | 2.2 | 4.1 | <0.001 | |
| 24.5 (2.9) | 24.8 (3.0) | 24.5 (2.9) | 24.3 (3.0) | 24.2 (3.0) | 24.2 (3.1) | <0.001 | |
| 114.6 (11.7) | 114.7 (11.8) | 114.4 (11.6) | 114.5 (11.7) | 115.0 (12.0) | 116.3 (12.8) | <0.001 | |
| 74.0 (9.4) | 74.0 (9.7) | 73.9 (9.4) | 74.0 (9.4) | 74.2 (9.3) | 74.8 (9.9) | <0.001 | |
| 98.4 (16.5) | 98.7 (18.1) | 98.1 (15.8) | 98.4 (16.4) | 99.2 (16.6) | 101.9 (22.0) | <0.001 | |
| 200.0 (34.6) | 200.6 (35.2) | 200.2 (34.4) | 199.6 (34.2) | 199.6 (35.5) | 198.8 (36.1) | 0.028 | |
| 127.4 (31.4) | 127.5 (31.7) | 127.6 (31.3) | 127.2 (31.2) | 127.2 (32.0) | 126.9 (32.5) | 0.159 | |
| 52.8 (12.7) | 52.8 (12.9) | 52.9 (12.7) | 52.8 (12.7) | 52.5 (12.8) | 51.5 (12.8) | <0.001 | |
| 115 (81–165) | 117 (82–169) | 114 (81–194) | 114 (81–163) | 115 (81–165) | 121 (84–176) | 0.002 | |
| 23 (17–34) | 24 (17–35) | 23 (17–34) | 23 (17–34) | 24 (17–34) | 24 (17–35) | 0.051 | |
| 1.28 (0.84–1.92) | 1.29 (0.84–1.97) | 1.27 (0.83–1.89) | 1.28 (0.84–1.92) | 1.32 (0.86–1.97) | 1.35 (0.85–2.09) | <0.001 | |
| 0.5 (0.3–1.0) | 0.6 (0.3–1.1) | 0.5 (0.3–1.0) | 0.5 (0.3–1.0) | 0.5 (0.3–1.1) | 0.6 (0.3–1.2) | <0.001 | |
| 1667.5 (1348.6–2056.4) | 1678.6 (1330.8–2093.3) | 1667.9 (1353.7–2053.3) | 1663.7 (1350.0–2042.7) | 1661.3 (1345.8- | 1673.2 (1344.9–2064.9) | 0.368 | |
| 14.8 | 32.9 | 14.9 | 8.5 | 6.6 | 10.0 | <0.001 | |
Data are expressed as
a mean (standard deviation)
c median (interquartile range), or percentage.
b ≥ 20 g of ethanol per day
d ≥ college graduate
e among 165,861 participants with plausible estimated energy intake levels (within three standard deviations from the log-transformed mean energy intake).
CVD, cardiovascular disease; ALT, alanine aminotransferase; BMI, body mass index; BP, blood pressure; HDL-C, high-density lipoprotein cholesterol; HEPA, health-enhancing physical activity; hsCRP, high sensitivity C-reactive protein; HOMA-IR, homeostasis model assessment of insulin resistance.
Baseline characteristics of study participants by sleep duration among women.
| Characteristics | Overall | Sleep duration (hours) | |||||
|---|---|---|---|---|---|---|---|
| ≤ 5 | 6 | 7 | 8 | ≥ 9 | |||
| 105,974 | 15,378 | 30,413 | 35,442 | 19,602 | 5,139 | ||
| 40.2 (9.7) | 41.8 (11.0) | 40.5 (9.6) | 39.9 (9.2) | 39.5 (9.5) | 39.1 (10.8) | <0.001 | |
| 64.6 | 69.4 | 68.8 | 63.8 | 58.4 | 54.1 | <0.001 | |
| 13.5 | 17.3 | 14.0 | 12.0 | 12.2 | 13.4 | <0.001 | |
| 2.5 | 3.7 | 2.6 | 2.0 | 2.2 | 2.3 | 0.022 | |
| 5.9 | 8.6 | 6.0 | 5.0 | 5.2 | 6.0 | 0.041 | |
| 15.0 | 16.2 | 15.3 | 15.0 | 14.2 | 12.5 | <0.001 | |
| 74.3 | 68.4 | 74.6 | 76.6 | 75.0 | 71.4 | 0.006 | |
| 82.4 | 76.6 | 79.4 | 84.2 | 87.5 | 87.0 | <0.001 | |
| 16.3 | 27.5 | 17.4 | 12.9 | 12.6 | 14.9 | <0.001 | |
| 7.0 | 10.0 | 7.1 | 6.0 | 6.4 | 7.0 | 0.038 | |
| 2.7 | 3.7 | 2.7 | 2.3 | 2.7 | 3.4 | 0.524 | |
| 0.9 | 1.4 | 0.9 | 0.8 | 0.8 | 1.1 | 0.021 | |
| 21.8 (3.0) | 22.2 (3.3) | 21.9 (3.1) | 21.6 (2.9) | 21.6 (3.0) | 21.6 (3.1) | <0.001 | |
| 102.5 (12.2) | 103.5 (12.8) | 102.5 (12.3) | 102.2 (12.1) | 102.2 (12.0) | 102.3 (12.0) | 0.003 | |
| 65.5 (8.7) | 66.1 (9.1) | 65.5 (8.8) | 65.3 (8.6) | 65.2 (8.6) | 65.2 (8.4) | <0.001 | |
| 92.3 (12.3) | 92.5 (13.1) | 92.2 (12.0) | 92.0 (11.5) | 92.4 (12.7) | 92.5 (14.3) | 0.013 | |
| 189.0 (33.3) | 191.7 (34.1) | 189.6 (33.1) | 188.5 (32.8) | 187.6 (33.4) | 186.9 (33.8) | <0.001 | |
| 111.4 (30.4) | 113.4 (31.7) | 111.5 (30.4) | 110.8 (29.8) | 110.9 (30.3) | 110.5 (30.5) | 0.001 | |
| 64.8 (14.8) | 64.9 (15.3) | 65.3 (14.6) | 65.1 (14.6) | 63.9 (14.4) | 63.2 (14.4) | <0.001 | |
| 72 (55–99) | 74 (56–103) | 71 (55–98) | 71 (55–96) | 72 (56–99) | 73 (56–102) | <0.001 | |
| 13 (11–18) | 14 (11–19) | 13 (11–18) | 13 (10–17) | 13 (10–18) | 13 (10–17) | <0.001 | |
| 1.06 (0.71–1.55) | 1.04 (0.69–1.57) | 1.04 (0.70–1.54) | 1.06 (0.72–1.53) | 1.08 (0.73–1.57) | 1.10 (0.74–1.61) | <0.001 | |
| 0.3 (0.2–0.7) | 0.3 (0.2–0.7) | 0.3 (0.2–0.7) | 0.3 (0.2–0.6) | 0.3 (0.2–0.7) | 0.3 (0.2–0.7) | <0.001 | |
| 1437.5 (1092.2–1810.2) | 1411.9 (1052.9–1808.1) | 1417.7 (1074.4–1793.4) | 1443.3 (1104.3–1806.0) | 1465.1 (1124.0–1824.4) | 1476.4 (1107.6–1861.2) | <0.001 | |
| 22.8 | 53.8 | 25.5 | 14.8 | 11.4 | 13.9 | <0.001 | |
Data are expressed as
a mean (standard deviation)
c median (interquartile range), or percentage.
b ≥ 20 g of ethanol per day
d ≥ college graduate
e among 165,861 participants with plausible estimated energy intake levels (within three standard deviations from the log-transformed mean energy intake).
CVD, cardiovascular disease; ALT, alanine aminotransferase; BMI, body mass index; BP, blood pressure; HDL-C, high-density lipoprotein cholesterol; HEPA, health-enhancing physical activity; hsCRP, high sensitivity C-reactive protein; HOMA-IR, homeostasis model assessment of insulin resistance.
Prevalence ratios (95% CI) of CKD and glomerular hyperfiltration by sleep duration and subjective sleep quality among men.
| Sleep duration (hours) | Subjective sleep quality | |||||||
|---|---|---|---|---|---|---|---|---|
| ≤5 | 6 | 7 | 8 | ≥9 | Good | Poor | ||
| 21,081 | 55,249 | 45,242 | 12,533 | 1,528 | 115,623 | 20,010 | ||
| | 113 (0.5) | 187 (0.3) | 210 (0.5) | 94 (0.8) | 40 (2.6) | 535 (0.5) | 109 (0.5) | |
| | 1.16 (0.92–1.46) | 0.73 (0.60–0.89) | Reference | 1.62 (1.27–2.07) | 5.88 (4.18–8.29) | <0.001 | Reference | 1.19 (0.97–1.46) |
| | ||||||||
| | 1.23 (0.97–1.56) | 0.93 (0.76–1.14) | Reference | 0.98 (0.76–1.27) | 1.52 (0.76–1.13) | 0.062 | Reference | 1.09 (0.87–1.36) |
| | 1.22 (0.95–1.55) | 0.93 (0.75–1.14) | Reference | 0.97 (0.75–1.26) | 1.56 (1.06–2.30) | 0.059 | Reference | 1.06 (0.84–1.32) |
| | 1,054 (5.0) | 2,571 (4.7) | 2,184 (4.8) | 624 (5.0) | 101 (6.6) | 5,449 (4.7) | 1,085 (5.4) | |
| | 1.04 (0.96–1.12) | 0.96 (0.91–1.02) | Reference | 1.04 (0.95–1.14) | 1.43 (1.16–1.76) | <0.001 | Reference | 1.16 (1.09–1.24) |
| | ||||||||
| | 1.01 (0.93–1.09) | 0.97 (0.91–1.02) | Reference | 1.03 (0.94–1.13) | 1.41 (1.14–1.74) | 0.001 | Reference | 1.10 (1.03–1.18) |
| | 1.00 (0.93–1.08) | 0.97 (0.91–1.03) | Reference | 1.03 (0.94–1.13) | 1.39 (1.13–1.72) | 0.002 | Reference | 1.09 (1.02–1.17) |
a Estimated from multinomial logistic regression models. Multivariable model 1 was adjusted for age, center, year of screening exam, smoking status, alcohol intake, physical activity, marital status, education level, total caloric intake, and depression; model 2 includes all of the variables from model 1 plus adjustment for history of diabetes, history of hypertension, and history of cardiovascular disease.
CKD, chronic kidney disease; BMI, body mass index; CI, confidence intervals; PR, prevalence ratio. CKD is defined as GFR < 60 ml/min per 1.73 m2.
Prevalence ratios (95% CI) of CKD and glomerular hyperfiltration by sleep duration and subjective sleep quality among women.
| Sleep duration (hours) | Subjective sleep quality | |||||||
|---|---|---|---|---|---|---|---|---|
| ≤5 | 6 | 7 | 8 | ≥9 | Good | Poor | ||
| 15,378 | 30,413 | 35,442 | 19,602 | 5,139 | 81.782 | 24,192 | ||
| | 54 (0.4) | 64 (0.2) | 69 (0.2) | 58 (0.3) | 21 (0.4) | 188 (0.2) | 78 (0.3) | |
| | 1.80 (1.26–2.58) | 1.08 (0.77–1.51) | Reference | 1.53 (1.08–2.18) | 2.15 (1.32–3.50) | 0.002 | Reference | 1.41 (1.09–1.84) |
| | ||||||||
| | 1.06 (0.73–1.54) | 1.02 (0.72–1.44) | Reference | 1.46 (1.02–2.09) | 1.31 (0.78–2.19) | 0.069 | Reference | 1.23 (0.93–1.63) |
| | 0.98 (0.68–1.43) | 1.03 (0.72–1.46) | Reference | 1.39 (0.97–2.00) | 1.31 (0.78–2.22) | 0.080 | Reference | 1.14 (0.86–1.52) |
| | 729 (4.7) | 1,364 (4.5) | 1,725 (4.9) | 1,105(5.6) | 348 (6.8) | 3,939 (4.8) | 1,332 (5.5) | |
| | 0.97 (0.89–1.06) | 0.92 (0.85–0.99) | Reference | 1.17 (1.08–1.26) | 1.42 (1.26–1.60) | <0.001 | Reference | 1.15 (1.08–1.23) |
| | ||||||||
| | 1.05 (0.95–1.14) | 0.97 (0.90–1.44) | Reference | 1.11 (1.03–1.20) | 1.29 (1.14–1.45) | <0.001 | Reference | 1.13 (1.06–1.21) |
| | 1.04 (0.95–1.14) | 0.96 (0.90–1.04) | Reference | 1.11 (1.02–1.20) | 1.28 (1.14–1.45) | <0.001 | Reference | 1.13 (1.06–1.21) |
a Estimated from multinomial logistic regression models. Multivariable model 1 was adjusted for age, center, year of screening exam, smoking status, alcohol intake, physical activity, marital status, education level, total caloric intake, and depression; model 2 includes all of the variables from model 1 plus adjustment for history of diabetes, history of hypertension, and history of cardiovascular disease.
CKD, chronic kidney disease; BMI, body mass index; CI, confidence intervals; PR, prevalence ratio. CKD is defined as GFR < 60 ml/min per 1.73 m2.